Conditions: Head and Neck Carcinoma; Adenoid Cystic Carcinoma; Lung Cancer; Non-Small Cell Lung Cancer; Pancreatic Cancer; Mesothelioma; Esophageal Cancer; Any Solid Tumors Progressed After a Prior Immunotherapy; Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma HNSCC; Salivary Gland Carcinomas; Head and Neck Cancers – Salivary Gland; Head and Neck Cancers – Nasopharyngeal; Head and Neck Cancers – Throat; Small Cell Lung Cancer ( SCLC ); Lung Cancer (Locally Advanced or Metastatic); Head and Neck Cancers – Tonsils; Head and Neck Cancers Hypopharynx; Head and Neck Cancers Larynx; Head and Neck Cancers Lip; Head and Neck Cancers Nasopharynx; Head and Neck Cancers Oral Cavity; Head and Neck Cancers; Head and Neck Cancers Oropharynx; Head and Neck Cancers Trachea
Interventions: Drug: VMD-928 100 mg Tablet; Drug: VMD-928 Tablet and Pembrolizumab (200 mg)
Sponsors: VM Oncology, LLC
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
